Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vericiguat

FDA-approved product (tablet, oral), marketed as Verquvo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vericiguat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other vasodilators used in cardiac diseases
FDA pharmacologic class
Soluble Guanylate Cyclase Stimulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vericiguat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vericiguat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The CardioMEMS Vericiguat Heart Failure Trial

    NCT06671990 · start 2024-12-01

    Registered record
    Registry ID
    NCT06671990
    Conditions
    Heart Failure; Pulmonary Arterial Hypertension
    Interventions
    Vericiguat; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2024-12-01
    Completion
    2026-01-31
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Pulmonary Arterial Hypertension
    InterventionVericiguat; Placebo
    PhasePhase 4
    Registry statusNot yet recruiting

  • An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan

    NCT06697353 · start 2024-11-01

    Registered record
    Registry ID
    NCT06697353
    Conditions
    Chronic Heart Failure; Chronic Heart Failure With Reduced Ejection Fraction
    Interventions
    vericiguat (BAY 1021189)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-11-01
    Completion
    2025-09-19
    Enrolment
    4,936

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure; Chronic Heart Failure With Reduced Ejection Fraction
    Interventionvericiguat (BAY 1021189)
    PhaseNot recorded
    Registry statusCompleted

  • Vericiguat in Patients With Coronary Microvascular Dysfunction Causing Stable Chest Pain (V-COM)

    NCT06239974 · start 2024-09-01

    Registered record
    Registry ID
    NCT06239974
    Conditions
    Chest Pain
    Interventions
    Vericiguat; Stress Cardiac Magnetic Resonance
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-09-01
    Completion
    2027-08-31
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChest Pain
    InterventionVericiguat; Stress Cardiac Magnetic Resonance
    PhaseNot applicable
    Registry statusRecruiting

  • An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany

    NCT06486844 · start 2024-07-05

    Registered record
    Registry ID
    NCT06486844
    Conditions
    Chronic Heart Failure With Reduced Ejection Fraction
    Interventions
    Vericiguat (Verquvo, BAY1021189)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-07-05
    Completion
    2025-08-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Reduced Ejection Fraction
    InterventionVericiguat (Verquvo, BAY1021189)
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years

    NCT06474208 · start 2024-07-01

    Registered record
    Registry ID
    NCT06474208
    Conditions
    Heart Failure
    Interventions
    Formulation 1; Formulation 2; Formulation 3; Formulation 4; Formulation 5 (placebo)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-07-01
    Completion
    2024-09-30
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionFormulation 1; Formulation 2; Formulation 3; Formulation 4 +1 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction

    NCT06195930 · start 2024-04-18

    Registered record
    Registry ID
    NCT06195930
    Conditions
    Chronic Heart Failure With Reduced Ejection Fraction
    Interventions
    Vericiguat (BAY1021189) 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2024-04-18
    Completion
    2024-07-29
    Enrolment
    106

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Reduced Ejection Fraction
    InterventionVericiguat (BAY1021189) 5 mg
    PhasePhase 2
    Registry statusCompleted

  • An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States

    NCT06363110 · start 2024-04-10

    Registered record
    Registry ID
    NCT06363110
    Conditions
    Chronic Heart Failure With Reduced Ejection Fraction
    Interventions
    Vericiguat (Verquvo, BAY1021189)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-04-10
    Completion
    2024-06-24
    Enrolment
    1,400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Reduced Ejection Fraction
    InterventionVericiguat (Verquvo, BAY1021189)
    PhaseNot recorded
    Registry statusCompleted

  • Effect of Vericiguat on Acute Coronary Syndrome( ACS）Patients With Ejection Fraction <45%

    NCT06321094 · start 2024-01-31

    Registered record
    Registry ID
    NCT06321094
    Conditions
    Acute Coronary Syndrome; Heart Failure With Reduced Ejection Fraction
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-01-31
    Completion
    2025-12-01
    Enrolment
    149

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome; Heart Failure With Reduced Ejection Fraction
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Vericiguat and Exercise Hemodynamics in Patients With HFrEF

    NCT07697365 · start 2024-01-31

    Registered record
    Registry ID
    NCT07697365
    Conditions
    Heart Failure With Reduced Ejection Fraction; Chronic Heart Failure
    Interventions
    Vericiguat; Guideline-directed medical therapy (GDMT) for heart failure
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-01-31
    Completion
    2025-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction; Chronic Heart Failure
    InterventionVericiguat; Guideline-directed medical therapy (GDMT) for heart failure
    PhaseNot recorded
    Registry statusCompleted

  • Impact of Vericiguat on Hemodynamics of Heart Failure

    NCT05704478 · start 2024-01-01

    Registered record
    Registry ID
    NCT05704478
    Conditions
    Heart Failure
    Interventions
    Vericiguat
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2024-01-01
    Completion
    2027-03-31
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionVericiguat
    PhasePhase 4
    Registry statusActive not recruiting

  • An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting

    NCT06148935 · start 2023-11-30

    Registered record
    Registry ID
    NCT06148935
    Conditions
    Chronic Heart Failure With Reduced Ejection Fraction
    Interventions
    Vericiguat (Verquvo, BAY1021189)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-11-30
    Completion
    2027-10-31
    Enrolment
    1,350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Reduced Ejection Fraction
    InterventionVericiguat (Verquvo, BAY1021189)
    PhaseNot recorded
    Registry statusRecruiting

  • Effect of Vericiguat on cardiAc Remodeling in Patients With Heart faiLure and Reduced Ejection fractioN (HFrEF): A Prospective sTudy usIng NOvel Echocardiographic Imaging Techniques (VALENTINO)

    NCT07472595 · start 2023-10-09

    Registered record
    Registry ID
    NCT07472595
    Conditions
    HFrEF - Heart Failure With Reduced Ejection Fraction
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-10-09
    Completion
    2025-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHFrEF - Heart Failure With Reduced Ejection Fraction
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Vericiguat in People With Breast Cancer and Cancer Therapy-Related Cardiac Dysfunction

    NCT05806138 · start 2023-07-17

    Registered record
    Registry ID
    NCT05806138
    Conditions
    Breast Cancer; Cardiac Dysfunction
    Interventions
    Vericiguat; Optimal medical therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-07-17
    Completion
    2028-07-17
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Cardiac Dysfunction
    InterventionVericiguat; Optimal medical therapy
    PhasePhase 2
    Registry statusActive not recruiting

  • The VERIFY Study: An Observational Study Called VERIFY to Learn More About the Use of Vericiguat in People With Chronic Heart Failure With Reduced Ejection Fraction

    NCT05974189 · start 2023-07-11

    Registered record
    Registry ID
    NCT05974189
    Conditions
    Chronic Heart Failure With Reduced Ejection Fraction
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2023-07-11
    Completion
    2024-10-08
    Enrolment
    1,391

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Reduced Ejection Fraction
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome

    NCT05697640 · start 2023-06-22

    Registered record
    Registry ID
    NCT05697640
    Conditions
    Post-COVID ME/CFS
    Interventions
    Vericiguat Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2023-06-22
    Completion
    2026-12-31
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-COVID ME/CFS
    InterventionVericiguat Oral Tablet
    PhasePhase 2
    Registry statusActive not recruiting